Ftse Mib
35.398,82
-0,03%
DAX
18.704,42
-0,11%
S&P 500
5.303,27
0,12%
NASDAQ
16.685,97
-0,07%
Bitcoin
66.838,42
-0,36%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Alimera Sciences Inc (ALIM) Alimera Sciences Inc (ALIM) Notizie

ALIM

Alimera Sciences (ALIM)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:ALIM
DataOraFonteTitoloSimboloCompagnia
16/05/202423:06Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:ALIMAlimera Sciences Inc
14/05/202423:04Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ALIMAlimera Sciences Inc
14/05/202414:46Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALIMAlimera Sciences Inc
14/05/202413:30GlobeNewswire Inc.Alimera Sciences Reports First Quarter 2024 ResultsNASDAQ:ALIMAlimera Sciences Inc
07/05/202414:00GlobeNewswire Inc.Alimera Announces Scientific Data Highlighting YUTIQ® to be Presented at Upcoming Association for Research in Vision and Ophthalmology and Retina World Congress ConferencesNASDAQ:ALIMAlimera Sciences Inc
30/04/202414:00GlobeNewswire Inc.Alimera Sciences to Report First Quarter 2024 Financial Results on May 14, 2024, and Provide Corporate UpdateNASDAQ:ALIMAlimera Sciences Inc
20/03/202413:00GlobeNewswire Inc.Alimera Sciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:ALIMAlimera Sciences Inc
19/03/202413:00GlobeNewswire Inc.Alimera Announces First Patient Randomized in Radiation Retinopathy Trial Being Conducted by the DRCR Retina NetworkNASDAQ:ALIMAlimera Sciences Inc
08/03/202423:23Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:ALIMAlimera Sciences Inc
07/03/202413:30GlobeNewswire Inc.Alimera Sciences Reports Fourth Quarter and Full Year 2023 ResultsNASDAQ:ALIMAlimera Sciences Inc
29/02/202414:00GlobeNewswire Inc.Alimera Sciences to Report Fourth Quarter and Full Year 2023 Financial Results on March 7, 2024, and Provide Corporate UpdateNASDAQ:ALIMAlimera Sciences Inc
13/02/202422:43Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:ALIMAlimera Sciences Inc
08/02/202414:00GlobeNewswire Inc.The UK National Institute for Health and Care Excellence (NICE) Issues Final Draft Guidance to Provide Patients with a Natural Lens (Phakic Eye) Being Treated for Chronic Diabetic Macular Edema Access to ILUVIEN®NASDAQ:ALIMAlimera Sciences Inc
11/01/202418:49Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALIMAlimera Sciences Inc
04/01/202422:02Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:ALIMAlimera Sciences Inc
04/01/202414:00GlobeNewswire Inc.Alimera Completes Recruitment for the Synchronicity StudyNASDAQ:ALIMAlimera Sciences Inc
02/01/202414:00GlobeNewswire Inc.Alimera Sciences Names Elliot Maltz as Chief Financial Officer and Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:ALIMAlimera Sciences Inc
12/12/202313:30GlobeNewswire Inc.Alimera Sciences Appoints Todd Wood as President of U.S. Operations and Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:ALIMAlimera Sciences Inc
08/11/202322:30GlobeNewswire Inc.Alimera Appoints Maggie A. Pax to Its Board of DirectorsNASDAQ:ALIMAlimera Sciences Inc
31/10/202313:00GlobeNewswire Inc.Alimera Announces Scientific Data Highlighting ILUVIEN® To Be Presented at the American Academy of OphthalmologyNASDAQ:ALIMAlimera Sciences Inc
26/10/202313:00GlobeNewswire Inc.Alimera Sciences Reports Third Quarter 2023 ResultsNASDAQ:ALIMAlimera Sciences Inc
16/10/202314:00GlobeNewswire Inc.Alimera Sciences to Report Third Quarter 2023 Financial Results on October 26, 2023, and Provide Corporate UpdateNASDAQ:ALIMAlimera Sciences Inc
11/10/202314:00GlobeNewswire Inc.Alimera Announces Multiple Presentations Highlighting ILUVIEN® and YUTIQ® Data at Retina Society Annual CongressNASDAQ:ALIMAlimera Sciences Inc
03/10/202314:00GlobeNewswire Inc.Alimera Sciences Appoints Jason Werner as Chief Operating OfficerNASDAQ:ALIMAlimera Sciences Inc
05/09/202314:00GlobeNewswire Inc.Alimera Sciences to Present at the H.C. Wainwright 25th Annual Global Investment ConferenceNASDAQ:ALIMAlimera Sciences Inc
23/08/202312:01Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:ALIMAlimera Sciences Inc
10/08/202313:30GlobeNewswire Inc.Alimera Sciences Reports Second Quarter 2023 ResultsNASDAQ:ALIMAlimera Sciences Inc
02/08/202317:43GlobeNewswire Inc.Alimera Sciences to Report Second Quarter 2023 Financial Results on August 10, 2023, and Provide Corporate UpdateNASDAQ:ALIMAlimera Sciences Inc
01/08/202322:47Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:ALIMAlimera Sciences Inc
13/07/202306:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:ALIMAlimera Sciences Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:ALIM

La tua Cronologia

BITMOT
973859
Kfw Green Tf 1,375% Fb28...
ASX
MUX
LSE
SOGP
Sovereign Oilfield
COIN
RC20USD
BIT
S31803
Societe Generale Effekten
BIT
F12537
Vontobel Financial Produ...
MRTX
ATMETH
ATMChain
LSE
PCGH
Polar Capital Global Hea...
COIN
CRAFTTUST
CRAFT
BOV
HAAA11
Hedge Aaa Fundo DE Inves...
COIN
OPENBTC
NYSE
FCT
First Trust Senior Float...
HITB
RNDRBTC
Render Token
LSE
0FME
Pittler Maschinenfabrik
COIN
SAPBTC
TG
EO5
Eog Resources
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network